Johnson & Johnson picked up a plant in Vacaville, California, nearly 20 years ago with its $10.5 billion buyout of Alza, a deal that also gave it attention-deficit disorder drug Concerta and cancer drug Doxil. Janssen is now focused in other areas and has decided the plant is no longer needed.
Nearly 50 employees are slated to be let go next week, according to a California WARN notice (PDF), as J&J’s pharmaceutical unit Janssen begins a three-year phaseout, a spokesman said in an email. The company declined to say how many total employees work there.
J&J says the closure is part of an effort to rework its manufacturing network as its drug portfolio changes.
“As part of this transformation, we will scale down production at our Vacaville, California facility with the intent to fully exit the site by the end of 2022,” J&J spokesman Matthew Johnson said.
Janssen, like other drugmakers, is putting more effort into areas such as immunology that involve biologic drugs. In the fourth quarter, sales of its Stelara worldwide grew by 33.6% on the back of its launch in Crohn’s disease, while psoriasis drug Tremfya has nabbed a 6.6% share of an ultracompetitive U.S. market since its July 2017 debut.
By Eric Palmer
Source: Fierce Pharma
AbbVie will be among the stocks closing out a busy earnings week. Earnings season tends to draw a lot of interest from investors, but it’s not always the best indicator of a stock’s overall trajectory.
Pfizer has bought privately held Amplyx Pharmaceuticals for an undisclosed sum, gaining experimental antifungal and antiviral treatments as the world’s attention turns more toward infectious diseases.
Surgical Theater’s technology builds 3D models of an individual patient’s anatomy from CT and MRI scans to offer surgeons an immersive, 360-degree fly-through view.